Information:
Fel:
ID
34597
Beskrivning
A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise; ODM derived from: https://clinicaltrials.gov/show/NCT01095653
Länk
https://clinicaltrials.gov/show/NCT01095653
Nyckelord
Versioner (1)
- 2019-01-19 2019-01-19 -
Rättsinnehavare
see on clinicaltrials.gov
Uppladdad den
19 januari 2019
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Type 2 Diabetes NCT01095653
Eligibility Type 2 Diabetes NCT01095653
- StudyEvent: Eligibility
Similar models
Eligibility Type 2 Diabetes NCT01095653
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
ID.1
Item
males and females, 18 years old, with type 2 diabetes and with inadequate glycemic control
boolean
ID.2
Item
drug naive or treated with anti-diabetic medication for < 24 weeks
boolean
ID.3
Item
c-peptide ≥ 1.0 ng/ml
boolean
ID.4
Item
body mass index ≤ 45.0 kg/m²
boolean
ID.5
Item
ast and/or alt > 3 times uln
boolean
ID.6
Item
serum total bilirubin > 2 mg/dl
boolean
ID.7
Item
serum creatinine ≥ 1.50 mg/dl for men or ≥ 1.40 mg/dl for women
boolean
ID.8
Item
creatine kinase ≥ 3 times uln
boolean
ID.9
Item
symptoms of severely uncontrolled diabetes
boolean
ID.10
Item
currently unstable or serious cardiovascular, renal, hepatic, hematological, oncological, endocrine, psychiatric, or rheumatic diseases
boolean